This IP centers around targeting immune checkpoint receptors, particularly TIM-3, to treat benign and malignant Schwann cell tumors. These tumors are associated with neurofibromatosis syndromes and pose significant health challenges due to their potential for malignant progression and limited treatment options. Schwann cell neoplasms, including schwannomas and malignant peripheral nerve sheath tumors (MPNSTs), lack effective therapies. The IP proposes leveraging immunotherapies to target TIM-3 and other checkpoint receptors present in the tumor microenvironment. This approach aims to reactivate the dysfunctional immune response within these tumors, potentially leading to improved treatment outcomes. Presently, there are no FDA-approved therapies for Schwann cell tumors. By targeting TIM-3, this IP introduces an innovative therapeutic approach that addresses an unmet medical need. Preclinical studies have shown promising results, indicating the potential effectiveness of anti-TIM-3 antibodies in blocking tumor growth. Immediate applications involve utilizing antibodies or small molecules to target TIM-3 and other immune checkpoint receptors for treating Schwann cell tumors. The technology opens avenues for combination therapies and future developments in the treatment of neurofibromatosis-related tumors. Pharmaceutical companies engaged in cancer immunotherapy may find this IP compelling for licensing. Given the growing interest in immunotherapies, there is significant market potential for treatments targeting immune checkpoint receptors. The IP has progressed from foundational research, including single-cell RNA sequencing analysis, to preclinical testing involving anti-TIM-3 antibody treatment in animal models. Further development aims to validate these findings in additional preclinical models and explore combination therapies.